National Institute of Mental Health Longitudinal Study of Chronic Schizophrenia: Prognosis and Predictors of Outcome

Archives of General Psychiatry

Volumn 48, Issue 3, 1991, Pages 239-246

  Breier, Alan ^a   Schreiber, Judith L ^b   Dyer, Janyce ^c   Pickar, David ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFFECTIVE NEUROSIS; ARTICLE; DRUG THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL HOSPITAL; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDE ATTEMPT;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; FRONTAL LOBE; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDIES; MALE; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); NEUROPSYCHOLOGICAL TESTS; PROBABILITY; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE, ATTEMPTED; UNITED STATES;

EID: 0025978419     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1991.01810270051007     Document Type: Article

References (59)

1. McGlashan TH. The Chestnut Lodge follow-up study, I: follow-up methodology and study sample. Arch Gen Psychiatry. 1984;41:573-585.
2. McGlashan TH. The Chestnut Lodge follow-up study, II: long-term out-come of schizophrenia and the affective disorders. Arch Gen Psychiatry. 1984;41:586-601.
3. Gardos G, Cole JO, LaBrie RA. A twelve-year follow-up study of chronic schizophrenics. Hosp Community Psychiatry. 1982;33:983-984.
4. Stone MH. Exploratory psychotherapy in schizophrenia-spectrum patients: a reevaluation in the light of long-term follow-up of schizophrenic and borderline patients. Bull Menninger Clin. 1986;50:287-306.
5. Engelhardt DM, Rosen B, Feldman J, Engelhardt JAZ, Cohen P. A 15year followup of 646 schizophrenic outpatients. Schizophr Bull. 1982;8:493-503.
6. Vaillant GE. An historical review of the remitting schizophrenias. J Nerv Ment Dis. 1964;138:48-56.
7. Vaillant GE. Prospective prediction of schizophrenic remission. Arch Gen Psychiatry. 1964;11:509-518.
8. Tsuang MT, Woolson RF, Fleming JA. Long-term outcome of major psychoses, I: schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch Gen Psychiatry. 1979;39:1295-1301.
9. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, I: methodology, study sample, and overall status 32 years later. Am J Psychiatry. 1987;144:718-726.
10. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 1987;144:727-735.
11. Bland RC, Parker JH, Orn H. Prognosis in schizophrenia: a ten-year followup of first admissions. Arch Gen Psychiatry. 1976;33:949-954.
12. Bland RC, Orn H. Fourteen-year outcome in early schizophrenia. Acta Psychiatr Scand. 1978;58:327-338.
13. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia, I: characteristics of outcome. Arch Gen Psychiatry. 1972;27:739-746.
14. Strauss JS, Carpenter WT. Prediction of outcome in schizophrenia, III: five-year outcome and its predictors. Arch Gen Psychiatry. 1977;34:159-163.
15. Loyd D, Simpson JC, Tsuang MT. Are there sex differences in the longterm outcome of schizophrenia? comparisons with mania, depression, and surgical controls. J Nerv Ment Dis. 1985;173:643-649.
16. Stephens JH. Long-term prognosis and followup in schizophrenia. Schizophr Bull. 1978;4:25-47.
17. McGlashan TH. Predictors of shorter-, medium-, and longer-term outcome in schizophrenia. Am J Psychiatry. 1986;143:50-55.
18. Fenton WS, McGlashan TH. Sustained remission in drug-free schizophrenics. Am J Psychiatry. 1987;144:1306-1309.
19. Tsuang MT, Woolson RF, Winokur G, Crowe RR. Stability of psychiatric diagnosis: schizophrenia and affective disorders followed up over a 30- to 40year period. Arch Gen Psychiatry. 1981;38:535-539.
20. Schreiber JL, Breier A, Pickar D. Referral patterns and patient selection for a schizophrenia research ward. Hosp Community Psychiatry. 1990;41:441-443.
21. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria (RDC). 3rd ed. New York, NY: New York State Psychiatric Institute; 1977.
22. Phillips L. Case history data and prognosis in schizophrenia. J Nerv Ment Dis. 1953;117:515-525.
23. Overall JE, Gorham DE. The Brief Psychiatric Rating Scale. Psychol Rep. 1961;10:799-812.
24. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39:748-788.
25. Hawk AB, Carpenter WT, Strauss JS. Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 1975;32:343-347.
26. Spitzer RL, Gibbon M, Endicott J. The Global Assessment Scale (GAS). New York, NY: New York State Psychiatric Institute; 1975.
27. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia-Lifetime Version. New York, NY: Biometrics Research Division; New York State Psychiatric Institute; 1975.
28. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry. 1987;144:1549-1555.
29. Stephens JH, Astrup C. Prognosis in ‘process’ and ‘non-process’ schizophrenia. Am J Psychiatry. 1963;119:945-953.
30. Ciompi L. Catamnestic long-term study of the course of life and aging of schizophrenics. Schizophr Bull. 1980;6:606-618.
31. Bleuler M. Die schizophrenen Geistesstorungen im Lichte langjahriger Kranken-und Familiengeschichten. New York, NY: Intercontinental Medical Book Corp; 1972.
32. Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6:592-605.
33. Pickar D, Labarca R, Doran AR, Wolkewitz OM, Roy A, Breier A, Linnoila M, Paul SM. Longitudinal measurements of plasma homovanillic acid in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry. 1986;43:669-676.
34. Fenton WS, McGlashan TH. Longitudinal perspectives on the deficit syndrome. Presented at the 142nd Annual Meeting of the American Psychiatric Association, May 4, 1989, San Francisco Calif.
35. Pfohl B, Winokur G. The micropsychopathology of hebephrenia/catatonic schizophrenia. J Nerv Ment Dis. 1983;5:296-300.
36. Harrow M, Carbone BJ, Westermmeyer JF. The course of psychosis in early phases of schizophrenia. Am J Psychiatry. 1985;142:702-707.
37. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF, and the Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients, II: two year relapse rate. Arch Gen Psychiatry. 1979;31:603-608.
38. Talbott JA. The Chronic Mental Patient: Problems, Solutions, and Recommendations for a Public Policy. Washington, DC: American Psychiatric Association; 1978.
39. Robins LN, Helzer JE, Weissman MM, Orraschel H, Gruenberg E, Burke JD Jr, Regier DA. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41:949-958.
40. Falloon I, Watt D, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med. 1978;8:59-70.
41. Knight A, Hirsch SL. ‘Revealed’ depression and drug treatment for schizophrenia. Arch Gen Psychiatry. 1981;38:806-811.
42. Roy A. Depression in the course of chronic undifferentiated schizophrenia. Arch Gen Psychiatry. 1981;38:296-300.
43. Johnson D. Studies of depressive symptoms in schizophrenia. Br J Psychiatry. 1981;139:89-102.
44. Miles CP. Conditions predisposing to suicide: a review. J Nerv Ment Dis. 1977;164:231-246.
45. Roy A. Suicide in schizophrenia. In: Roy A, ed. Suicide. Baltimore, Md: Williams & Wilkins; 1986.
46. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
47. Fuster J. The Prefrontal Cortex. New York, NY: Raven Press; 1980.
48. Miller MH. Dorsolateral frontal lobe lesions and behavior in the macaque: dissociation of threat and aggression. Phsysiol Behav. 1976;17:209-213.
49. Raleigh MJ, Steklis HD, Ervin FR, Kling AS, McGuire MT. The effects of orbitofrontal lesions on the aggressive behavior of vervet monkeys (Cercopithecus aethiops sabaeus). Exp Neurol. 1979;66:158-168.
50. Peters M, Ploog D. Frontal lobe lesions and social behavior in the squirrel monkey (Saimiri): a pilot study. Acta Biol Med Germ. 1976;35:1317-1326.
51. Stuss DT, Benson DF. The Frontal Lobes. New York, NY: Raven Press; 1986.
52. Volkow ND, Wolf AP, Van Gelder P, Brodie JD, Overall JE, Cancro R, Gomez-Mont F. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry. 1987;144:151-158.
53. Besson JAO, Corrigan FM, Cherryman GR, Smith FW. Nuclear magnetic resonance brain imaging in chronic schizophrenia. Br J Psychiatry. 1987;150:161-163.
54. Andreasen N, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry. 1982;39:789-794.
55. Harding CM. Course types in schizophrenia: an analysis of European and American studies. Schizophr Bull. 1988;14:633-643.
56. Huber G, Gross G, Schuttler R. A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatr Scand. 1975;52:49-57.
57. Bleuler M; Clemens SM, trans. The Schizophrenic Disorders. New Haven, Conn: Yale University Press; 1978.
58. Carpenter WT, Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr Bull. 1988;14:645-652.
59. Wong DF, Wagner HN Jr, Dannals RF, Links JM, Frost JJ, Ravert HT, Wilson AA, Rosenbaum AE, Gjedde A, Douglass KH, Petgnis JD, Folstein MF, Toung JKT, Burns D, Kuhar MJ. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 1984;226:1393-1396.